Asston Pharmaceuticals Limited has scheduled a board meeting on July 2, 2026, to consider a proposal for raising funds. The board will evaluate various methods for the capital raise, including a preferential issue, subject to necessary regulatory and statutory approvals as well as shareholder authorization.

The decision to explore fund-raising options comes as the company seeks to bolster its financial resources. The preferential issue, if approved, would require the consent of the shareholders of the company. The meeting agenda includes reviewing these proposals to determine the most suitable path forward for the capital infusion.

In conjunction with the board meeting, the company has announced the closure of the trading window for its securities. This measure is in line with the Company's Code of Conduct framed under the SEBI (Prohibition of Insider Trading) Regulations, 2015. The restriction is effective from June 24, 2026, and will remain in place until July 4, 2026, inclusive of both dates.

During this period, all connected persons and designated persons are advised not to trade in the listed securities or any proposed to be listed securities of the company. This step is intended to ensure compliance with insider trading norms and maintain market integrity ahead of the board's decision.

The intimation was submitted to BSE Limited pursuant to Regulation 29 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015. Rishi Upadhaya, Company Secretary & Compliance Officer, signed the disclosure on behalf of the Board of Directors.

asston pharmaceuticals reported a net profit of ₹386.52 lakh for the financial year ended March 31, 2026, with revenue from operations rising to ₹2,546.88 lakh. The company’s board approved the audited financial results for the year and half-year ended March 31, 2026, during a meeting held on May 29, 2026. The statutory auditors, M/s Panchal S K & Associates, issued an unmodified opinion on the standalone financial results.

For the year ended March 31, 2026, the company recorded a total income of ₹3,158.43 lakh, compared to ₹2,561.02 lakh in the previous year. Total expenses for the period stood at ₹2,699.09 lakh, up from ₹2,059.42 lakh in FY25. The profit before tax for the year was ₹459.35 lakh, while the tax expense totaled ₹72.83 lakh.

The half-year results for the period ended March 31, 2026, showed a revenue from operations of ₹1,005.29 lakh and a net profit of ₹48.30 lakh. In comparison, the half-year ended March 31, 2025, reported a revenue of ₹906.85 lakh and a net profit of ₹195.17 lakh. The company noted that the figures for the half-year ended March 31, 2026, and March 31, 2025, are balancing figures derived from the audited annual results and unaudited half-yearly figures.

The earnings per share (EPS) for the year ended March 31, 2026, stood at ₹4.92 on an annualised basis, down from ₹6.14 in the previous year. The paid-up equity share capital increased to ₹851.24 lakh as of March 31, 2026, from ₹627.14 lakh in the prior year. The company’s reserves and surplus also saw a significant rise, reaching ₹3,034.99 lakh compared to ₹476.47 lakh in FY25.

Financial Results for FY26

Assets and Liabilities

The company’s total assets as of March 31, 2026, stood at ₹5,164.55 lakh, a significant increase from ₹2,812.31 lakh in the previous year. Shareholders' funds grew to ₹3,886.22 lakh, driven by the increase in equity share capital and reserves. Non-current liabilities were recorded at ₹379.40 lakh, while current liabilities stood at ₹898.92 lakh.

The cash flow statement for the year ended March 31, 2026, reflected a net increase in cash and cash equivalents of ₹109.17 lakh. Cash generated from operations was negative at ₹1,017.95 lakh, primarily due to working capital changes. However, financing activities provided a net cash inflow of ₹2,117.87 lakh, largely attributed to the issue of equity share capital.